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SUMMARY. The aim ot fhe present work was to compare the penetration in muscle tissue fluid (MTF)
and muscle tissue (MT) of cephalotin administered in rabbits. Animals were distributed in Trial 1 (n = 15)
and Trial 2 ( n= 6). In the Trial 1 the animals were implanted in ischiotibial muscle with non reactive ma-
terial cages. Animals recibed  subcutaneously (sc) cephalotin (20 mg/kg) and blood, MTF and MT samples
were recollected. In the Trial 2 the animals recibed cephalotin (20 mg/kg) intravenously (iv) and blood
samples were recollected. Pharmacokinetic analysis were performed using a non-compartmental model.
Results: terminal disposition rate constant (λz) (serum iv) 1.43 ± 0.54, (serum sc) 1.90, (MTF) 0.57 and
(MT) 1.80 h–1; elimination half-life (t1/2) (serum iv) 0.53 ± 0.13, (serum sc) 0.36, (MTF) 1.20 and (MT) 0.38
h; the area under the curve [AUC(0-6)] (serum iv) 60.40 ± 38.20, (serum sc) 45.90, (MTF) 21.60 and (MT)
3.00 μg.ml–1.h. and the bioavailability (F) was 76%. The penetration of cephalotin in MTF and MT were
47.70 and 6.43%, respectively. Cephalotin administered subcutaneously in rabbit presented higher
bioavailability, distribution in extracelullar fluid and low penetration in muscle tissue.
RESUMEN. “Penetración de Cefalotina en Líquido Tisular de Músculo y Tejido Muscular”. Los objetivos del
presente trabajo fueron comparar la penetración in líquido tisular de músculo (MTF) y tejido muscular (MT) de
cefalotina administrada a conejos. Los animales fueron distribuidos en Experimento 1 (n = 15) y Experimento 2
(n = 6). En el Experimento 1 los conejos fueron implantados en tejido muscular con cajas confeccionadas con
material no reactivo. Posteriormente recibieron subcutáneamente (sc) cefalotina (20 mg/kg) y se recolectaron
muestras de sangre, MTF y MT. En el Experimento 2 los animales recibieron cefalotina (20 mg/kg) vía endove-
nosa (iv) y se recolectaron muestras de sangre. El análisis farmacocinético fue realizado utilizando un modelo no
compartimental. Resultados: constante de velocidad de eliminación (λz) (suero iv) 1,43 ± 0,54, (suero sc) 1,90,
(MTF) 0,57 y (MT) 1,80 h–1; tiempo medio de eliminación (t1/2) (suero iv) 0,53 ± 0,13, (suero sc) 0,36, (MTF)
1,20 y (MT) 0,38 h; área bajo la curva [AUC(0-6)] (suero iv) 60,40 ± 38,20, (suero sc) 45,90, (MTF) 21,60 y
(MT) 3,00 μg.ml–1.h y biodisponibilidad (F) 76%. La penetración de cefalotina en MTF y MT fue de 47,70 y
6,43%, respectivamente. La cefalotina administrada subcutáneamente en conejos presentó alta biodisponibilidad,
distribución en líquido extracelular y baja penetración en tejido muscular.
INTRODUCTION
Cephalosporins are antibiotics chemically re-
lated to penicillins. Both have in common a be-
ta-lactamic ring as part of their structure. These
antibiotics interfere with the normal synthesis of
the bacterial cell wall and are effective against
the majority of the Gram-positive cocci and
some Gram-negative bacilli such as Escherichia
coli, Proteus mirabilis and Klebsiella pneumoni-
ae 1.
Cephalotin is a first-generation cephalosporin
whose pharmacokinetics have been studied in
various animal species 2-4 as well as in humans
5,6. Overall this antibiotic is poorly absorbed in
the digestive tract and thus has to be adminis-
tered parenterally to obtain a systemic effect. It
is distributed mainly in the extracellular fluid
and excreted by the kidneys 1.
The implantation of cages in animals was
performed for the first time by Chisholm et al. 7
in order to determine the concentration of an-
tibacterial agents into interstitial tissue fluid. This
method has further been used to study the
mechanisms and courses of the inflammatory re-
sponses in tissues and the distribution of drugs
8-10. There is information about the distribution
of betalactamics in muscle tissue fluid 11. How-
ever, there is no bibliographical data on the
concentration-time course of cephalotin in mus-
cle tissue fluid, and on how those concentra-
tions resemble the ones found in muscle tissue.
The aim of the present work was to compare
the penetration of cephalotin into muscle tissue




Twenty-one New Zealand White male rabbits
weighing approximately 2 kg. were obtained
from the Department of Introduction to Animal
Production, Faculty of Agricultural and Forestry
Sciences of La Plata University and distributed at
random in Trial 1 (n = 15) and Trial 2 (n = 6).
Animals were kept in individual cages on a cli-
mate-controlled environment and fed with a
commercial diet and water ad libitum. The re-
search protocol was approved by the Commis-
sion of Scientific Research of the Province of
Buenos Aires.
Trial 1
Implantation of the cages in muscle tissue for the
collection of muscle tissue fluid (MTF)
Thirty-nine animals were implanted in the is-
chiotibial muscle non-reactive material cages.
Each animal had one cage implanted intramus-
cularly (semitendinous muscle, left or right). The
cages consisted of Silastic (Dow Corning, Mid-
land, MI) rubber tubes, 20.0 mm long and 5.0
mm inner diameter, closed at one end, with 40%
of its surface perforated by 1.0 mm holes. For
this purpose, the area of the ischiotibial muscle
was shaved, washed and disinfected. Implanta-
tion sites were anesthetized with Lidocaine 2%
and cages were inserted into the muscle,
through a skin incision in the mentioned areas.
The percentage of protein binding in MTF
fluid was calculated by comparation of antimi-
crobial activity of cephalotin in presence and
absence of protein 12. For that, were compared
the halos of inhibition of standard curves of
cephalotin in MTF and buffer.
Biochemical determinations
Muscle tissue fluid and blood/serum samples
were collected at days 15, 30 and 60 after the
implantation of the cages and postadministration
of antibiotic. Samples were analyzed for total
proteins by the Biuret method and for albumin
by binding sulfobromophthalein in order to de-
termine the reaction to the implanted material.
Antibiotic, route of administration and doses
Animals with stabilized cages received sub-
cutaneously a single dose of cephalotin (20
mg/kg). Blood samples (0.2 ml each one) were
obtained (three animals at a time and one sam-
ple per animal) by direct venipuncture of the
saphenous vein 13 immediately before the ad-
ministration of the drug and at 0.08, 0.17, 0.25,
0.5, 1.0, 2.0, 4.0 and 6.0 h postadministration of
the antibiotic.
Sampling of MTF and muscle tissue
Immediately after taking the blood samples,
the animals were sacrificed by cervical disloca-
tion, then samples of MTF and muscle tissue
(semitendinous muscle oposited to the implant-
ed muscle) were taken starting at 0.25 hours
postadministration of the antibiotic, in equal
times to the blood sampling.
Processing and preservation of the samples
Blood samples were allowed to clot and
then centrifuged at 3000 g for 15 min in order to
separate the serum. Muscle tissue samples were
weighted, diluted in phosphate-buffered saline
solution and homogenized with a hand homog-
enizer. All the samples were stored in individu-
al, sterile recipients at -18 °C, until being ana-
lyzed.
Trial 2
Blood samples were obtained at the same
time and by the same method as in Trial 1, in
order to make the biochemical determinations.
Antibiotic, route of administration and doses
Animals received a single intravenous dose
of cephalotin (20 mg/kg) (left saphenous vein)
and blood samples (0.2 ml each one) were col-
lected in each animal by direct venipuncture of
the right saphenous vein at 0.08, 0.17, 0.25, 0.5,
1.0, 2.0, 4.0 and 6.0 h postadministration of the
antibiotic. The blood samples were processed
and stored in the same way as in Trial 1.
Quantification of the antibiotic
The concentrations of cephalotin in serum,
MTF and muscle tissue were determined by
means of the microbiological assay technique,
using Bacillus stearothermophilus var. calidolac-
tis as the test organism 14. The antibiotic solu-
tions used as standard lines in serum, MTF and
muscle tissue were prepared in pooled normal
rabbits serum, serum diluited 1:2 in phosphate-
buffered saline solution and muscle tissue ho-
mogenate supernatant diluted 1:2 in phosphate-
buffered saline solution (obtained by centrifuga-
tion at 3000 g for 15 min), respectively. The cor-
relation coefficient for the standard curves pre-
pared for all experiments was greater than 0.98.
The coefficients of variation intra- and inter- as-
says were lower than 8% and the limit of sensi-
tivity of the assay was 0.01 µg/ml. The pharma-
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cokinetic parameters λz, and t1/2 in MTF and
muscle have not been statistically assessed be-
cause they were calculated from the concentra-
tions-time means of each group of animals.
Pharmacokinetics
The following pharmacokinetic parameters
were determined. The apparent terminal half-life
(t1/2) and the area under the serum concentra-
tion-time curve (AUC0-6) were estimated by
noncompartmental analysis with WinNonlin
software (version 4.1; Pharsight Corp., Cary,
NC).
The percentage of bioavailability (F) was cal-
culated by using the Eq. [1]
(AUC(0-6) sc) 
F = x 100 [1]
(AUC(0-6) iv)
The penetration (P) of cephalotin into MTF
and muscle tissue (MT) was calculated by the
Eq. [2]
[AUC(0-6) (MTF or MT)]
P = x 100 [2]
(AUC(0-6) serum)
In order to compare the serum and muscle
tissue concentrations, the linear regression anal-
ysis was employed. The pharmacokinetic data
(AUC0-6), the interaction between the serum and
muscle tissue concentrations and the biochemi-
cal results, were analyzed by means of variance
analysis (ANOVA).
RESULTS AND DISCUSSION
Since 15 days untill 60 days postimplantation
of the cages to collect MTF were considered as
stabilized and the total average protein concen-
tration in MTF was lower to 55% of that ob-
tained in serum samples.
The total protein and albumin levels in
serum and MTF at 1, 3 and 6 h postadministra-
tion of cephalotin were statistically similar (see
Table 1).
The cephalotin percentage of protein bind-
ing in MTF was 30%. The time-concentration
(means ± standard desviation) values and phar-
macokinetic variables in serum, MTF and mus-
cle tissue of cephalotin administered parenteral-
ly to rabbits are presented in Figure 1 and Table
2, respectively.
During the period from 0.5 to 4 h after the
administration of cephalotin by intravenous and
subcutaneous routes, the antibiotic levels in
serum were 33.21 ± 26.20 to 0.68 ± 0.40 and
64.11 ± 11.20 to 0.07 ± 0.04 µg/ml, respectively.
Concentration (g/dl) in serum/ MTF
Parameter
1 h 3 h 6 h
Total protein 4.9/2.6 5.0/2.9 4.4/2.5
Albumin 3.7/1.6 4.3/1.5 4.0/1.6
Table 1. Mean total protein and albumin concentra-
tions in serum and muscle tissue fluid (MTF) at differ-
ent times postadministration of cephalotin.
Meanwhile, the concentrations of cephalotin
in MTF and muscle tissue during the periods
from 0.5 to 6.0 h and from 0.5 to 4.0 h were
11.51 ± 6.60 to 0.52 ± 0.42 and 4.60 ± 0.17 to
0.01 µg/ml, respectively.
The half-life of elimination values in serum
of cephalotin administered by intravenous and
subcutaneous routes to rabbits (0.53 ± 0.13 and
0.36 h, respectively) were similar to those ob-
tained by Bush et al. 3 in avian species (from 16
to 54 min) and humans obtained by Kirby &
Regamey 5 (from 28 to 51 min) and Barza et al. 6
(0.34 h) and greater than the obteined by Rule
et al. 4 in goats (0.2 h) and Bergeron et al. 2 in
rabbits (15.8 min).
The half-lives of elimination of cephalotin in
MTF and tissue muscle were 1.20 and 0.38 h, re-
spectively. The higher value in MTF could be
explained by means of this formula: SA/V to as-
sess the concentrations of drugs in extracellular
fluid 15, where SA is the surface of the available
area for the diffusion of the drug and V (vol-
ume) represents the distance of diffusion. The
low relation between the surface area and the
volume of the tissue cages used in our work,
could account for the artificial increase in the
half-life obtained in MTF compared to the val-
ues in serum. The half-lives in serum and mus-
cle tissue were similar, which would indicate a
relatively strong relationship between serum
and muscle tissue concentrations with equal
correlation coefficients (0.901). The P value is
lower than 0.01 and there is a statistically signifi-
cant correlation between concentrations at the
99% confidence level.
Penetration of cephalotin in MTF and muscle
tissue were 47.70 and 6.43% of the values ob-
tained in serum, respectively. On the other
hand, the obtained volume of distribution of
cephalotin (245.60 ± 78.95 ml.kg–1) in our work,
would be indicating that its pasagge is mainly
realized into extracellular fluid and scarcely to
muscle tissue.
Considering that only the free cephalotin in
serum and MTF is distributed in muscle tissue,
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and its binding to serum proteins and MTF in
rabbits is 50 2 and 30%, respectively. The ob-
tained concentrations represented approximate-
ly 100 and 20% of antibiotic, respectively. 
In conclusion, as cephalotin is a lipophilical-
ly-poor drug and has a low distribution its pas-
sage to the intracellular fluid becomes restricted;
so, if we take into account the concentrations
found in extracellular fluid when considering
the values in muscle tissue, we can erroneously
estimate the concentrations in this tissue.
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